|Bid||3.710 x 1400|
|Ask||3.740 x 800|
|Day's Range||3.6892 - 3.9850|
|52 Week Range||3.2100 - 7.6000|
|Beta (3Y Monthly)||2.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2019 - Mar 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.50|
Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for FMX101 for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. “Submission of this NDA is yet another important milestone for Foamix, and potentially brings us one step further to commercial launch of FMX101,” commented David Domzalski, Chief Executive Officer.
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying for a while now that the current market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth quarter, […]
A look at the shareholders of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to Read More...
Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the appointment of Matt Wiley as Chief Commercial Officer. “Matt has an exceptional commercial record in pharmaceuticals and brings valuable experience and depth of knowledge in marketing, market access, and product launches,” said David Domzalski, Chief Executive Officer of Foamix. Matt Wiley joins Foamix with more than 20 years of commercial experience across a broad range of specialty pharmaceutical categories.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 19) Merck & Co., Inc. (NYSE: MRK ) Down In The Dumps (Biotech ...
Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the appointment of Anthony Bruno to its Board of Directors, replacing Darrell Rigel, M.D. who has resigned from the Board and will become a consultant to the company. “We are delighted to welcome Tony to our Board of Directors,” said Dr. Stanley Hirsch, Chairman of the Board of Foamix.
NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Foamix (FOMX) delivered earnings and revenue surprises of -22.58% and -21.36%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Conference Call and Webcast Thursday, November 8, @ 8.30 am Eastern Time REHOVOT, Israel, Nov. 07, 2018 -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the.
Foamix Pharmaceuticals Ltd said on Wednesday its experimental foam treatment for rosacea, a common skin condition that causes acne-like bumps and redness on the face, met the main goals of two late-stage clinical trials. The treatment, code-named FMX103 and made up of an antibiotic commonly used to treat infections, significantly reduced inflammatory lesions, compared to a foam without the antibiotic, minocycline. The two late-stage studies enrolled over a thousand patients suffering from papulopustular rosacea, which causes lesions to break out on the face, and the mostly commonly reported side effects were upper respiratory tract infections, the company said.
FMX103 Demonstrated Highly Statistically Significant Improvement Compared with Vehicle in Both Co-Primary Efficacy Endpoints Conference Call and Webcast Today at 8:30.
REHOVOT, Israel, and BRIDGEWATER, N.J., Oct. 29, 2018 -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on.
If you own shares in Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
NEW YORK, NY / ACCESSWIRE / September 13, 2018 / U.S. markets were mixed on Wednesday as technology shares declined, dragging the Nasdaq into the red. The Dow Jones Industrial Average climbed 0.11 percent ...
HENDERSON, NV / ACCESSWIRE / September 12, 2018 / One company that has been explosive in the past is Propanc Biopharma, Inc. (PPCB). PPCB is a very interesting biotech play. PPCB is a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors, such as pancreatic, ovarian and colorectal cancers.